Arginase activity in patients with breast cancer: An analysis of plasma, tumors, and its relationship with the presence of the estrogen receptor

Onkologie

Volumn 35, Issue 10, 2012, Pages 570-574

  Perez, Gabriel ^a   Olivares, Ivonne M ^b   Rodriguez, Magdalena G ^c   Ceballos, Guillermo M ^b   Sanchez, Jose R Garcia ^b  

^a Hospital General Regional No 72   (Mexico)

^b INSTITUTO POLITÉCNICO NACIONAL   (Mexico)

^c Faculty of Healthy Science   (Mexico)

Author keywords

Arginase; Estrogen receptor; Tumor

Indexed keywords

ARGINASE; ESTROGEN RECEPTOR;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER GROWTH; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; PLASMA; TUMOR BIOPSY;

ADULT; AGED; ARGINASE; BREAST NEOPLASMS; ENZYME ACTIVATION; FEMALE; HUMANS; MEXICO; MIDDLE AGED; PREVALENCE; RECEPTORS, ESTROGEN; REPRODUCIBILITY OF RESULTS; RISK FACTORS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 84867259175     PISSN: 0378584X     EISSN: 14230240     Source Type: Journal    
DOI: 10.1159/000343005     Document Type: Article

References (25)

1. Ferra C, Marcos P, Misis M, Morgades M, Knaul FM, Nigenda G, Lozano R, Arreola OH, Langer A, Frenk J: Breast Cancer in Mexico: a pressing priority. Reprod Health Matters 2008;32:113-123.
2. Palacio-Mej? LS, Lazcano-Ponce E, Allen-Leigh B, Hern?dez-Avila M: Regional differences in breast and cervical cancer mortality in Mexico between 1979-2006. Salud Publica Mex 2009;51(suppl 2): S208-S219.
3. Manni A: Polyamine involvement in breast cancer phenotype. In Vivo 2002;16:493-500.
4. Levue J, Foucher F, Bansard JY, Havouis R, Grall JY, Moulinoux JP: Polyamine profiles in tumor, normal tissue of the homologous breast, blood, and urine of breast cancer sufferers. Breast Cancer Res Treat 2000;60:99-105.
5. Morris SM Jr: Recent advances in arginine metabolism: roles and regulation of the arginases. Br J Pharmacol 2009;157:922-930.
6. Wu G, Flynn NE, Knabe DA, Jaeger LA: A cortisol surge mediates the enhanced polyamine synthesis in porcine enterocytes during weaning. Am J Physiol Regulatory Integrative Comp Physiol 2000; 279:R554-R559.
7. Dizikes GJ, Grody WW, Kern RM, Cederbaum SD: Isolation of human liver arginase cDNA and demonstration of nonhomology between the two human arginase genes. Biochem Biophys Res Commun 1986;141:53-59.
8. Takiguchi M, Haraguchi Y, Mori M: Human liver-type arginase gene: structure of the gene and analysis of the promoter region. Nucleic Acids Res 1988;16:789-802.
9. Obtake A, Takiguchi M, Shigeto Y, Amaya Y, Kawamoto S, Mori M: structural organisation of gene for rat-liver-type arginase. J Biol Chem 1988; 263:2245-2249.
10. Gotoh T, Araki M, Mori M: Chromosomal localisation of the human arginase II gene and tissue distribution of its mRNA. Biochem Biophys Res Commun 1997;233:487-491.
11. Satriano J: Arginine pathways and the inflammatory response: interregulation of nitric oxide and polyamines. Amino Acids 2004;26:321-329.
12. Deignan JL, Livesay JC, Shantz LM, Pegg AE, O'Brien WE, Iyer RK, Cederbaum SD, Grody WW: Polyamine homeostasis in arginase knockout mice. Am J Physiol Cell Physiol 2007;293:C1296-1301.
13. Nelin LD, Chicoine LG, Reber KM, English BK, Young TL, Liu Y: Cytokine-induced endothelial arginase expression is dependent on epidermal growth factor receptor. Am J Respir Cell Mol Biol 2005;33:394-401.
14. Manni A, Trout D, Verderame MF, Washington S, Mauger D, Demers L: Effect of alpha-difluoromethyl-ornithine on the expression and function of the epidermal growth factor receptor in human breast epithelial cells in culture. Breast Cancer Res Treat 2001;68:139-146.
15. Pegg AE: Regulation of ornithine decarboxylase. J Biol Chem 2006;26;281: 14529-1432.
16. Qin C, Samudio I, Ngwenya S, Safe S: Estrogen-dependent regulation of ornithine decarboxylase in breast cancer cells through activation of nongenomic cAMPdependent pathways. Mol Carcinog 2004;40:160-170.
17. Corraliza IM, Campo ML, Soler G, Modolell M: Determination of arginase activity in macrophages: a micromethod. J Immunol Methods 1994;174:231-235.
18. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ: Protein measurement with the folin phenol reagent. J Biol Chem 1951;19:265-275.
19. Finek J, Holubec L Jr, Topolcan O, Elgrova L, Skalova A, Pecen L: The importance of prognostic factors in premenopausal women with breast cancer. Anticancer Res 2007;27:1893-1896.
20. Straus B, Cepelak I, Festa G: Arginase, a new marker of mammary carcinoma. Clin Chim Acta 1992;210:5-12.
21. Cavdar Z, Onvural B, Guner G: Arginase in patients with breast cancer. Clin Chim Acta 2003;338:171-172.
22. Polat MF, Taysi S, Polat S, B A, Bakan E: Elevated serum arginase activity levels in patients with breast cancer. Surg Today 2003;33:655-661.
23. Porembska Z, Luboiski G, Chrzanowska A, Mielczarek M, Magnuska J, Baraczyk-Kuma A: Arginase in patients with breast cancer. Clin Chim Acta 2003;328:105-111.
24. Stuart-Harris R, Shadbolt B, Palmqvist C, Chaudri Ross HA: The prognostic significance of single hormone receptor positive metastatic breast cancer: an analysis of three randomised phase III trials of aromatase inhibitors. Breast 2009;18:351-355.
25. Elledge RM, Green S, Pugh R, Allred DC, Clark GM, Hill J, Ravdin P, Martino S, Osborne CK: Estrogen receptor (ER) and progesterone receptor (PgR), by ligand-binding assay compared with ER, PgR and pS2, by immuno-histochemistry in predicting response to tamoxifen in metastatic breast cancer: a Southwest Oncology Group Study. Int J Ccer 2000;89:111-117.